development of novel therapies for pediatric cancer

Engineered T Cells: CAR T Cell Therapy and Beyond

Purpose of review: This article reviews the current data and future directions of engineered T cell therapies in non-Hodgkin lymphomas. Recent findings: Currently, four chimeric antigen receptor (CAR) T cell products are approved: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel. These products differ in construct, indication, manufacturing, clinical trial design, and toxicity profile, but all are autologous products targeting CD19. Encouraging early data is also emerging with the use of these products in additional subtypes of B cell lymphoma. Alternative engineered T cell products are also in development, including dual CD19/22 targeting CAR T cells, CD30-directed CAR T cells, allogeneic CAR…
Read More
development of novel therapies for pediatric cancer

development of novel therapies for pediatric cancer

DESCRIPTION (offered by applicant): Pediatric cancers are orphan malignancies that happen in sufferers who've traditionally been missed for essentially the most half by the pharmaceutical and biotechnology industries; thus, the pediatric cancers could be thought-about double orphans" - orphan ailments that happen in orphan sufferers. Although dramatic strides have been achieved over the previous 40 years within the administration of the pediatric cancers, there stay many shortcomings within the efficacies and toxicities of accessible therapies for the varied varieties of childhood malignancy. development of novel therapies for pediatric cancer The main objective of this utility is to facilitate the development of new applied…
Read More
No widgets found. Go to Widget page and add the widget in Offcanvas Sidebar Widget Area.